Benign Prostatic Hyperplasia Prostate Treatment Market Size & Share, by Treatment Type (Drug, Surgical Treatment); Therapeutic Class {BPH Devices (Transurethral RF Thermal Therapy, Suture Base Implant), BPH Drugs (Alpha Blocker, Muscarinic Receptor Antagonist, 5-Alpha Reductase Inhibitors)}; Distribution Channel (Pharmacies, Online, Institutional Sales) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4218
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Cardinal Health Inc.
    • NxThera, Inc.
    • Veru, Inc.
    • Teleflex Incorporated
    • Eli Lily & Company
    • Sanofi S.A.
    • GSK plc
    • Mylan N.V.
    • AbbVie Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • Teleflex Incorporated announced the results of research studies regarding the efficacy and safety of UroLift systems. The system is developed for men diagnosed with benign prostatic hyperplasia (BPH) and median lobe obstruction.

  • Veru Inc. announced that it has received approval by the United States Food and Drug Administration (FDA) for its finasteride and tadalafil capsules, known as ENTADFI, which is used to treat urinary tract symptoms caused as a result of an enlarged prostate, commonly known as BPH.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4218
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher prevalence of benign prostatic hyperplasia (BPH), developing medical technology across the globe, increasing healthcare expenditure per capita, and spiking cases of urinary tract infection are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Government initiatives regarding the sales and consumption of medicines, and lack of awareness of the disease in developing countries are estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Cardinal Health Inc., NxThera, Inc., Veru, Inc., Teleflex Incorporated, Eli Lily & Company, Sanofi S.A., GSK plc, Mylan N.V., AbbVie Inc., Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by therapeutic class, distribution channel, treatment type, and by region

The drug treatment segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying